Heru

Heru Inc. (www.SeeHeru.com) has developed patented autonomous AI-powered vision diagnostics and augmentation software for use on commercially available AR/VR devices. This technology exceeds traditional standards of care in clinical equivalence, usability, cost, size, and portability. Heru is the only cross-platform solution that can autonomously diagnose vision defects and customize individual vision augmentation based on the user’s unique vision defects.

Heru originated as a spinout from Bascom Palmer Eye Institute. In December 2020, Heru announced FDA registration and a seed round led by Fred Drasner, Maurice R. Ferre, M.D., Fred H. Moll, M.D., and a consortium of investors with extensive experience developing, launching, and scaling cutting-edge medical technologies.

Heru headquartered in United States, North America, operates in the Augmented Reality, Virtual Reality, Artificial Intelligence (AI), Medical Device, Health Diagnostics sector. The company focuses on Augmented Reality and has secured $1.3B in funding across 40 round(s). With a team of 51-100 employees, Heru is actively contributing to advancements in Augmented Reality. Their latest funding round, Seed Round - Heru, raised $2.7M. Discover more about their projects, partnerships, and impact on our platform.